Department of Rheumatology, Key Laboratory of Myositis; Beijing Key Laboratory for Immune Mediated Inflammatory Diseases, China-Japan Friendship Hospital, Beijing, China.
Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing, China
RMD Open. 2024 Apr 5;10(2):e003931. doi: 10.1136/rmdopen-2023-003931.
We aimed to explore a new and readily available practical marker for rapidly progressive interstitial lung disease (RP-ILD) and poor short-term outcomes in patients with idiopathic inflammatory myopathies (IIM).
A total of 1822 consecutive patients with IIM between 2009 and 2021 were evaluated retrospectively. All proven cases of naïve ILD with complete medical records were included. Red cell distribution width (RDW) values at the initial stage, 3 months and last follow-up were collected. The clinical characteristics and outcomes of the patients were recorded.
We identified 532 patients with IIM with an average follow-up of 4 years. ILD prevalence was higher in patients of elevated RDW (p<0.001). The patients with ILD and elevated RDW had lower levels of PaO/FiO, FVC% and DLco% and a higher prevalence of RP-ILD than those with normal RDW (p<0.001). Prognostic analysis revealed that RDW was an independent risk factor for prognosis in patients with IIM-ILD (HR=2.9, p=0.03). Patients with dermatomyositis (DM) with RP-ILD with a change in RDW within 3 months (∆RDW-3) greater than 0 were more likely to die within 3 months. Moreover, the prevalence of ∆RDW-3>0 was higher in patients with RP-ILD and positive for anti-melanoma differentiation-associated gene 5 antibody who died within 3 months (87.5%) compared with those alive at 3 months (24.6%) (p<0.001).
These findings suggest that repeated RDW assays could assist physicians in identifying patients with DM-ILD who were at a high risk of RP-ILD and death.
本研究旨在探索一种新的、易于获得的实用标志物,用于快速进展性间质性肺病(RP-ILD)和特发性炎症性肌病(IIM)患者的短期不良预后。
回顾性分析了 2009 年至 2021 年间连续 1822 例 IIM 患者。所有纳入的病例均为初治ILD,且有完整的病历记录。收集患者初诊时、3 个月和末次随访时的红细胞分布宽度(RDW)值,记录患者的临床特征和结局。
本研究共纳入 532 例 IIM 患者,平均随访 4 年。RDW 升高的患者ILD 患病率更高(p<0.001)。与 RDW 正常的患者相比,ILD 合并 RDW 升高的患者 PaO/FiO、FVC%和 DLco%更低,RP-ILD 患病率更高(p<0.001)。预后分析显示,RDW 是 IIM-ILD 患者预后的独立危险因素(HR=2.9,p=0.03)。3 个月内 RDW 变化(∆RDW-3)大于 0 的合并 RP-ILD 的皮肌炎(DM)患者更有可能在 3 个月内死亡。此外,3 个月内死亡的患者中,∆RDW-3>0 的发生率高于存活至 3 个月的患者(87.5% vs. 24.6%,p<0.001),且这些患者中抗黑色素瘤分化相关基因 5 抗体阳性的比例更高。
这些发现提示,反复检测 RDW 有助于医生识别出 DM-ILD 患者中 RP-ILD 和死亡风险较高的患者。